AKT1 and non-small cell lung carcinoma: In several non-small cell lung cancer (NSCLC) cell lines, IGFBP-3 acts as a potent inhibitor of IGF-1R signaling by interfering with both the MAPK and PI-3K/Akt signaling pathways, resulting in growth arrest and inducing apoptosis [8].